# Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory Disease

> **NCT02216357** · PHASE2 · COMPLETED · sponsor: **Cumberland Pharmaceuticals** · enrollment: 19 (actual)

## Conditions studied

- Aspirin Exacerbated Respiratory Disease (AERD)

## Interventions

- **DRUG:** Ifetroban, Oral Capsule
- **DRUG:** Placebo, Oral Capsule

## Key facts

- **NCT ID:** NCT02216357
- **Lead sponsor:** Cumberland Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2017-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02216357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02216357, "Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02216357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*